ARROWHEAD PHARMACEUTICALS IN (ARWR)
US04280A1007 - Common Stock
| 2024 (2024-9-30) | 2023 (2023-9-30) | 2022 (2022-9-30) | 2021 (2021-9-30) | 2020 (2020-9-30) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 99.19M | 103.00M | 108.00M | 184.40M | 143.60M | |||
| Marketable Securities | 578.28M | 292.70M | 268.40M | 183.40M | 171.90M | |||
| Receivables | N/A | 0.00 | 1.40M | 10.30M | 800.00K | |||
| Other Current Assets | 18.01M | 23.80M | 27.50M | 6.60M | 6.10M | |||
| Total Current Assets | 695.47M | 419.50M | 405.30M | 384.60M | 322.40M | |||
| Non-Current Assets | ||||||||
| PPE Net | 431.29M | 335.60M | 168.60M | 66.00M | 47.00M | |||
| Investments And Advances | N/A | 0.00 | 105.90M | 245.60M | 137.50M | |||
| Intangibles | 8.56M | 10.30M | 12.00M | 13.70M | 15.40M | |||
| Other Non-Current Assets | 4.48M | 200.00K | 200.00K | 300.00K | 300.00K | |||
| Total Non-Current Assets | 444.33M | 346.10M | 286.60M | 325.50M | 200.10M | |||
| TOTAL ASSETS | 1.14B | 765.60M | 691.90M | 710.10M | 522.50M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 91.35M | 68.30M | 61.90M | 26.00M | 14.50M | |||
| Accounts Payable | 11.39M | 35.90M | 2.90M | 9.50M | 6.80M | |||
| Other Current Liabilities | 432.00K | 1.30M | 74.10M | 111.10M | 19.30M | |||
| Total Current Liabilities | 103.17M | 105.50M | 138.90M | 146.50M | 40.70M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 393.18M | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 452.39M | 372.90M | 134.80M | 154.80M | 20.00M | |||
| Total Non-Current Liabilities | 851.19M | 388.70M | 154.50M | 154.80M | 20.00M | |||
| TOTAL LIABILITIES | 954.36M | 494.20M | 293.40M | 301.30M | 60.70M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.63B | -1.03B | -820.80M | -644.70M | -503.80M | |||
| Additional Paid In Capital | 1.81B | 1.30B | 1.22B | 1.05B | 965.40M | |||
| Minority Interest | 5.62M | 15.80M | 19.80M | N/A | 0.00 | |||
| Common Shares | 217.00K | 200.00K | 200.00K | 200.00K | 200.00K | |||
| Other Shareholders' Equity | 4.75M | -3.20M | -100.00K | -100.00K | 0.00 | |||
| Shares Outstanding | 124.38M | 107.30M | 106.00M | 104.30M | 102.40M | |||
| Tangible Book Value per Share | 1.42 | 2.43 | 3.65 | 3.79 | 4.36 | |||
| Total Shareholders' Equity | 185.44M | 271.30M | 398.50M | 408.80M | 461.80M | |||
| TOTAL LIABILITIES AND EQUITY | 1.14B | 765.60M | 691.90M | 710.10M | 522.50M | |||
| Statistics | ||||||||
| Debt/Equity | 2.12 | N/A | N/A | N/A | N/A | |||
| Current Ratio | 6.74 | 3.98 | 2.92 | 2.63 | 7.92 | |||
| Return On Assets (ROA) | -52.60% | -26.82% | -25.45% | -19.83% | -16.19% | |||
| Return On Equity (ROE) | -323.27% | -75.67% | -44.19% | -34.44% | -18.32% | |||
| Return On Invested Capital (ROIC) | N/A | N/A | N/A | N/A | N/A | |||
All data in USD , ROIC based on taxRate of 0.21